1 / 2

FLT3-mut

Studie Aktiv. Studie in Vorbereitung. Keine aktuelle Studie. AML. Rezidiv. Primärtherapie. LENA. Aura-3. Aggressive Behandlung möglich?. Ja. Nein. Lenalidomid. Aura PHA-739358. AML-BI. AraC +/- BI811283. Mutationen?. Ja. Nein. Keine Mutationen. CBF. FLT3-mut. FAB M3. NPM1-mut.

duard
Télécharger la présentation

FLT3-mut

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Studie Aktiv Studie in Vorbereitung Keine aktuelle Studie AML Rezidiv Primärtherapie LENA Aura-3 Aggressive Behandlung möglich? Ja Nein Lenalidomid AuraPHA-739358 AML-BI AraC +/- BI811283 Mutationen? Ja Nein Keine Mutationen CBF FLT3-mut FAB M3 NPM1-mut < 60 > 60 CIARA Dasatinib GIMEMA ATRA+ICE AML-Pfizer AML-Novartis "3+7 " +/-Clofarabine "3+7 " / Dasatinib ATRA+Arsen vs Pethema ATRA+ICE +/- Myelotarg "3+7 "+SU11248 "3+7 " +/- PKC 412 Ansprechpartner: Prof. Fiedler, J. Granzow (-7843), M. v. d. Born (-4354) Stand 01.11.2008

More Related